PLATFORM: Planning treatment of oesophago-gastric (OG) cancer-A randomised maintenance therapy trial

Catherine Cafferkey, Ian Chau, Fiona Thistlethwaite, Russell Petty, Naureen Starling, David Watkins, Sheela Rao, Claire Saffery, Bijal Patel, Clare Peckitt, David Cunningham.

    Research output: Contribution to journalArticlepeer-review


    Background: Outcomes for patients with advanced OG cancer remain poor, median overall survival for fit patients treated with platinum and fluoropyrimidine based chemotherapy is less than one year, with second line chemotherapy resulting in a modest (approximately 6 weeks) survival benefit for selected patients. Evidence from NSCLC trials suggests a survival benefit from maintenance treatment following first line chemotherapy. Emerging data also supports the use of immunotherapy in previously treated OG cancer. The PLATFORM study aims to evaluate maintenance therapy in patients with advanced OG cancer.

    Methods: This is a prospective, open label, multicentre, randomised phase II clinical trial which will recruit at multiple UK cancer centres. Eligible patients are those who have measurable stable disease or better following completion of first line chemotherapy (at least 6 cycles) for locally advanced unresectable or metastatic disease. First line chemotherapy regime should contain a platinum and 5-fluoropyridimine (with trastuzumab if HER2 +), doublet or triplet drug combinations are permitted. Maintenance strategies are split by HER 2 status. For HER2 negative patients these are: Arm A1: surveillance, Arm A2: capecitabine, Arm A3: MEDI 4736 (anti PDL1 inhibitor) and for HER2 positive patients; Arm B1: trastuzumab, Arm B2: in development. Target recruitment is six hundred and sixteen patients, 154 patients will be recruited to each arm, with an interim analysis following recruitment of 61 patients to each arm. An adaptive trial design enables ineffective treatments to be discontinued early, with the opportunity to add novel treatment arms as the trial progresses. Primary endpoint is progression free survival. Secondary endpoints are progression free rate at 3, 6 & 12 months, overall survival, objective response rate by RECIST 1.1, toxicity and analysis of efficacy endpoints according to biomarker status for selected arms. Thirty two patients have been registered for the study with 3 patients randomised, recruitment is ongoing.

    Clinical trial information: EUDRACT: 2014-002169-30.
    Original languageEnglish
    Article numberTPS187
    JournalJournal of Clinical Oncology
    Issue number4_Suppl
    Publication statusPublished - 2016


    Dive into the research topics of 'PLATFORM: Planning treatment of oesophago-gastric (OG) cancer-A randomised maintenance therapy trial'. Together they form a unique fingerprint.

    Cite this